Get the Stockscreener App
4.26
2.52%
-0.11
After Hours:
4.24
-0.02
-0.47%
Aquestive Therapeutics Inc stock is traded at $4.26, with a volume of 4.85M.
It is down -2.52% in the last 24 hours and up +10.94% over the past month.
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States.
See More
Previous Close:
$4.37
Open:
$4.26
24h Volume:
4.85M
Relative Volume:
1.06
Market Cap:
$519.73M
Revenue:
$43.40M
Net Income/Loss:
$-68.98M
P/E Ratio:
-8.2526
EPS:
-0.5162
Net Cash Flow:
$-50.94M
1W Performance:
+3.65%
1M Performance:
+10.94%
6M Performance:
-21.40%
1Y Performance:
+52.69%
1-Day Range:
$4.135
$4.50
1-Week Range:
$3.86
$4.50
52-Week Range:
$2.12
$7.55
Aquestive Therapeutics Inc Stock (AQST) Company Profile
Name
Aquestive Therapeutics Inc
Sector
Phone
908-941-1900
Address
30 TECHNOLOGY DRIVE, WARREN, NJ
Compare AQST vs TAK, ZTS, HLN, TEVA, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AQST
Aquestive Therapeutics Inc
|
4.26 | 533.15M | 43.40M | -68.98M | -50.94M | -0.5162 |
|
TAK
Takeda Pharmaceutical Co Adr
|
17.76 | 57.56B | 29.85B | 776.90M | 4.35B | 0.2408 |
|
ZTS
Zoetis Inc
|
122.23 | 53.17B | 9.47B | 2.67B | 2.28B | 6.0218 |
|
HLN
Haleon Plc Adr
|
10.33 | 46.62B | 14.54B | 2.22B | 2.58B | 0.4879 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
31.75 | 38.33B | 17.41B | 1.43B | 1.00B | 1.2182 |
|
UTHR
United Therapeutics Corp
|
485.06 | 21.48B | 3.13B | 1.27B | 1.12B | 26.39 |
Aquestive Therapeutics Inc Stock (AQST) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-02-25 | Resumed | Oppenheimer | Outperform |
| Dec-17-24 | Initiated | Cantor Fitzgerald | Overweight |
| May-10-24 | Initiated | Leerink Partners | Outperform |
| Apr-11-24 | Initiated | Piper Sandler | Overweight |
| Mar-28-24 | Initiated | Raymond James | Outperform |
| Apr-07-21 | Resumed | RBC Capital Mkts | Outperform |
| Apr-22-19 | Initiated | H.C. Wainwright | Buy |
| Jan-03-19 | Initiated | Lake Street | Buy |
| Aug-20-18 | Initiated | JMP Securities | Mkt Outperform |
| Aug-20-18 | Initiated | RBC Capital Mkts | Outperform |
View All
Aquestive Therapeutics Inc Stock (AQST) Latest News
Aquestive (AQST) Q4 2025 Earnings Call Transcript - AOL.com
Earnings call transcript: Aquestive Therapeutics Q4 2025 misses forecast, stock dips - Investing.com India
INVESTIGATION NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Aquestive Therapeutics - Barchart.com
Aquestive Therapeutics, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Aquestive's Q4 Net Loss Widens Despite Revenue Growth; Issues FY26 Guidance - Nasdaq
Aquestive Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update - Investing News Network
Compared to Estimates, Aquestive Therapeutics (AQST) Q4 Earnings: A Look at Key Metrics - Yahoo Finance
Aquestive Therapeutics: Fourth Quarter Financial Results Overview - Bitget
Aquestive Therapeutics earnings missed by $0.13, revenue fell short of estimates - Investing.com Canada
Aquestive Therapeutics (AQST) Reports Q4 Loss, Misses Revenue Estimates - Yahoo Finance
Aquestive Therapeutics Inc. (AQST) Stock Falls on Q4 2025 Earnings - Quiver Quantitative
Aquestive Therapeutics Q4 Loss Widens, Revenue Rises; Shares Fall After Hours - marketscreener.com
Aquestive Therapeutics Amends RTW Deal, Strengthens Financing Outlook - TipRanks
Aquestive Therapeutics (NASDAQ:AQST) Posts Quarterly Earnings Results, Misses Expectations By $0.13 EPS - MarketBeat
Aquestive Therapeutics: Q4 Earnings Snapshot - KING5.com
Regulatory setbacks hit Aquestive (NASDAQ: AQST) lead drugs Anaphylm, Libervant - Stock Titan
Anaphylm CRL and 2025 loss shape Aquestive (NASDAQ: AQST) outlook - Stock Titan
Aquestive Therapeutics Q4 Earnings Assessment - Benzinga
Trading Recap: How does Aquestive Therapeutics Inc score in quality rankingsJuly 2025 Action & Low Volatility Stock Recommendations - baoquankhu1.vn
A Preview Of Aquestive Therapeutics's Earnings - Benzinga
AQST SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Aquestive Therapeutics - Nasdaq
AQST Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Aquestive Therapeutics, Inc.Common Stock (NQ: AQST - The Chronicle-Journal
Aquestive Therapeutics Inc (AQST) - MSN
AQST INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims o - GuruFocus
AQST INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Aquestive Therapeutics - PR Newswire
Aquestive Therapeutics Inc. (AQST) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Aquestive Therapeutics Touts Anaphylm, Targets Q3 FDA Resubmission After CRL at Oppenheimer Conference - MarketBeat
Lake Street adjusts Aquestive Therapeutics, Inc. (AQST) valuation model on expected approval delay - MSN
INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Aquestive Therapeutics - ChartMill
Aquestive Highlights Strategy, Pipeline and Risk Disclosures - TipRanks
Aquestive Therapeutics files investor presentation detailing Anaphylm plan, CRL resubmission timeline and cash position - TradingView
Aquestive Therapeutics Forms Death Cross, Signaling Potential Bearish Trend - Markets Mojo
Aquestive Therapeutics to Participate in Upcoming March Investor Conferences - Investing News Network
Aquestive Therapeutics (AQST) to Release Earnings on Wednesday - MarketBeat
AQST INVESTIGATION ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Aquestive Therapeutics - marketscreener.com
Aquestive Therapeutics to Report Fourth Quarter 2025 Financial Results and Recent Business Highlights on March 4 and Host Conference Call on March 5 at 8:00 a.m. ET - Investing News Network
Aquestive Therapeutics to Report Fourth Quarter 2025 - GlobeNewswire
Lake Street Adjusts Aquestive Therapeutics, Inc. (AQST) Valuation Model on Expected Approval Delay - Insider Monkey
Aquestive Therapeutics to Participate in Oppenheimer 36th Annual Healthcare Life Sciences Conference - Bitget
625,000 Shares in Aquestive Therapeutics, Inc. $AQST Acquired by Aberdeen Group plc - MarketBeat
Is Aquestive Therapeutics Inc. forming a bullish divergenceJuly 2025 Setups & Free High Return Stock Watch Alerts - mfd.ru
Aquestive Therapeutics to Present New Clinical Data on Anaphylm (dibutepinephrine) Sublingual Film at the 2026 AAAAI Annual Meeting - Bitget
Aquestive Therapeutics Announces Clinical Results for Anaphylm™ Sublingual Film at AAAAI Annual Meeting - Quiver Quantitative
Allergy film Anaphylm delivers epinephrine without blood pressure dip in study - Stock Titan
Aquestive Therapeutics, Inc. (NASDAQ:AQST) Given Average Recommendation of "Buy" by Analysts - MarketBeat
Aquestive Therapeutics Appoints Internationally Recognized Allergist Dr. Matthew Greenhawt as Chief Medical Officer - The Globe and Mail
Analyst Upgrade: Will Aquestive Therapeutics Inc benefit from government policyQuarterly Growth Report & Weekly High Conviction Ideas - baoquankhu1.vn
Aquestive appoints allergy expert Dr. Greenhawt as chief medical officer - Investing.com
2026-02-18 | Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Aquestive Therapeutics, Inc. (AQST) and Encourages Shareholders to Learn More About the Investigation | NDAQ:AQST | Press Release - Stockhouse
Aquestive Therapeutics Inc Stock (AQST) Financials Data
Revenue
Net Income
Cash Flow
EPS
Aquestive Therapeutics Inc Stock (AQST) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Jung Cassie | Chief Operating Officer |
Oct 15 '25 |
Option Exercise |
3.10 |
25,000 |
77,568 |
308,346 |
| Jung Cassie | Chief Operating Officer |
Oct 15 '25 |
Sale |
7.01 |
67,575 |
473,701 |
240,771 |
| Kraus Carl N | Chief Medical Officer |
Oct 15 '25 |
Sale |
7.00 |
20,272 |
141,904 |
282,475 |
| Boyd Peter E. | See Remarks |
Oct 15 '25 |
Sale |
7.00 |
10,000 |
70,000 |
268,323 |
0.07%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):